<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332552</url>
  </required_header>
  <id_info>
    <org_study_id>115040</org_study_id>
    <nct_id>NCT01332552</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects</brief_title>
  <official_title>A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed&#xD;
      for the treatment of chronic HCV infection. HBI115040 is the first administration of&#xD;
      GSK2485852 in humans to establish the initial safety, tolerability, pharmacokinetic, and&#xD;
      antiviral profile. The study design is a fusion of single and repeat dosing cohorts in HCV&#xD;
      infected subjects to evaluate the safety, pharmacokinetics, and antiviral activity of&#xD;
      GSK2485852.&#xD;
&#xD;
      HBI115040 describes a Phase I, randomized, double-blind, placebo-controlled, dose escalation&#xD;
      fusion study to determine the safety, tolerability, pharmacokinetic, and antiviral profile of&#xD;
      GSK2485852 in single doses (Part 1), repeat doses (Part 2), and ritonavir co-administration&#xD;
      (Part 3) in chronically infected HCV subjects. The study will also explore the effect of a&#xD;
      moderate (30%) fat meal on pharmacokinetic endpoints in HCV subjects in Part 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to unfavorable human pharmacokinetic properties&#xD;
  </why_stopped>
  <start_date type="Actual">January 14, 2011</start_date>
  <completion_date type="Actual">April 6, 2011</completion_date>
  <primary_completion_date type="Actual">April 6, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters: adverse events; telemetry; absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs (blood pressure, heart rate), and electrocardiogram (ECG) parameters</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2485852 PK parameters following single dose administration: AUC(0-inf), AUC(0-t), AUC(0-24), Cmax, tmax, C24, t1/2, tlag, and CL/F</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2485852 PK parameters following repeat dose administration: AUC(0-τ), Cτ, Cmax, tmax, t1/2, and CL/F</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV RNA viral load reduction from baseline</measure>
    <time_frame>24 to 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV RNA change from baseline to nadir</measure>
    <time_frame>up to 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of HCV viral load at baseline, during dosing with GSK2485852, and &gt; or = 14 days after GSK2485852 dosing</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 PK parameters: AUC(0-24), Cmax, tmax and tlag following a single dose with and without moderate fat/calorie meal.</measure>
    <time_frame>24 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 accumulation ratio (R)</measure>
    <time_frame>72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 time invariance in non-food cohorts</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 dose proportionality after single or repeat dosing in non-food cohorts</measure>
    <time_frame>up to 72 h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: GSK2485852 + Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 70 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 420 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Repeat dose, once daily for 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 420 mg</intervention_name>
    <description>Repeat dose, twice daily for 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 420 mg</intervention_name>
    <description>Repeat dose, TIDfor 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 630 mg</intervention_name>
    <description>Repeat dose, twice daily for 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 70 mg + Ritonavir 100mg</intervention_name>
    <description>single dose, day 1</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 210 mg + Ritonavir 100mg</intervention_name>
    <description>single dose, day 1</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 210 mg +Ritonavir 100mg</intervention_name>
    <description>single dose daily for 3 days</description>
    <arm_group_label>Part 3: GSK2485852 + Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A subject will be eligible for inclusion in this study only if all of the following&#xD;
             criteria apply: Healthy as determined by a responsible and experienced physician,&#xD;
             based on a medical evaluation including medical history, physical examination,&#xD;
             laboratory tests and cardiac monitoring (i.e., ECG), including no cardiac, pulmonary,&#xD;
             hepatic, biliary, gastrointestinal, or renal disorders, or cancer within the past 5&#xD;
             years.&#xD;
&#xD;
          -  Males or females between 18 and 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of non-childbearing potential.&#xD;
&#xD;
          -  Body weight &gt; or = 50 kg (110 lbs.) for men and &gt; or = 45 kg (99 lbs.) for women and&#xD;
             BMI between 18.5-35.0 kg/m2 inclusive will be allowed.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  AST, ALT, and alkaline phosphatase &lt;3.0xULN and bilirubin &lt;1.5xULN (isolated bilirubin&#xD;
             &gt;1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Average QTcB or QTcF &lt; 450 msec; or QTcB or QTcF &lt; 480 msec in subjects with Bundle&#xD;
             Branch Block.&#xD;
&#xD;
          -  Treatment naive chronically infected HCV subjects, defined as infection for &gt;6 months&#xD;
             and no prior HCV therapy, with an HCV RNA viral load of greater than 100,000 IU/mL and&#xD;
             HCV genotype 1a or 1b. HCV subjects with mixed genotypes are not eligible for the&#xD;
             study.&#xD;
&#xD;
          -  Positive for HCV RNA and anti-HCV antibody at the time of screening AND positive for&#xD;
             anti-HCV antibody, HCV RNA, or an HCV genotype at least 6 months before screening; OR&#xD;
             Positive for HCV RNA and anti-HCV antibody at the time of screening AND liver biopsy&#xD;
             within three years prior to screening indicating the absence of cirrhosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or HIV antibody within 3 months of&#xD;
             screening.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior&#xD;
             to the first dose of study medication.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer). Exposure to more than four new&#xD;
             investigational products within 12 months prior to the first dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication,&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Holter monitoring shows one or more of the following: Any symptomatic arrhythmia&#xD;
             (except isolated extra systoles); Sustained cardiac arrhythmias (such as atrial&#xD;
             fibrillation or flutter, SVT (&gt;10 consecutive beats)); Sustained tachycardia &gt;150&#xD;
             beats per minute; Non-sustained or sustained ventricular tachycardia (defined as &gt;3&#xD;
             consecutive ventricular ectopic beats); Any conduction abnormality (including but not&#xD;
             specific to left or right complete bundle branch block, AV block [2nd degree or higher&#xD;
             in an awake subject], WPW syndrome, other pre-excitation syndromes); Symptomatic sinus&#xD;
             pause or sinus pause &gt;3 seconds - unless patient is straining, vomiting, or having&#xD;
             some other type of hypervagal response; 300 or more supraventricular ectopic beats in&#xD;
             24 hours; 250 or more ventricular ectopic beats in 24 hours; Ischemia, diagnosed by a&#xD;
             sequence of ECG changes that include flat or downsloping ST-segment depression &gt;0.1&#xD;
             mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each&#xD;
             episode of ischemia must be separated by a minimum duration of at least 1 minute,&#xD;
             during which the ST segment returns back to baseline (1x1x1 rule).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>First administration to human</keyword>
  <keyword>antiviral activity</keyword>
  <keyword>safety</keyword>
  <keyword>hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

